IRW-PRESS: Mind Medicine Mindmed Inc. : MindMed baut sein Arzneimittelspektrum und seine
Führungsrolle in der Branche für Psychedelika-Medikamente weiter aus

MindMed Co-founders and Co-CEOs JR Rahn and Stephen Hurst to provide corporate update of
activities and investor Q&A on July 2, 2020 at 1pm EST

Basel, Switzerland -- June 26, 2020-MindMed (DE:MMQ) , the leading neuro-pharmaceutical company
for psychedelic inspired medicines is rapidly advancing its drug development pipeline and R&D
activities since its listing on March 3, 2020.

MindMed Co-Founder and Co-CEO JR Rahn said Our progress in the past few months clearly
demonstrates the quality of our team and the pace at which we operate as a company. We are honored
to pioneer the fast growing psychedelic inspired medicines industry alongside peers including
COMPASS Pathways, ATAI Life Sciences and non-profits MAPs, USONA and the Heffter Institute. There is
a very clear distinction of the caliber of organizations advancing clinical trials to develop
disruptive medicines for mental health and addiction and we look forward to continually raising the
bar for the entire space and patients.

In furtherance of its mission to discover, develop and deploy psychedelic inspired medicines the
company and management have executed on the below selected opportunities since listing on March 3,
2020:

LSD (lysergic acid diethylamide) 

Experiential Therapies 
- Added an ongoing Phase 2 clinical trial evaluating high dose LSD for the treatment of anxiety
disorders in collaboration with the University Hospital Basels Liechti Lab.
- Initiated Project Lucy, a high dose LSD psychedelic assisted therapy drug commercial
development program for the treatment of anxiety disorders, intending to undertake a Phase 2b human
trial.
- Added and began treating patients in a Phase 2 clinical trial of LSD for Cluster Headaches in
collaboration with University Hospital Basels Liechti Lab.
- Filed a patent application for a LSD neutralizer technology intended to shorten and stop the
effects of an LSD trip during a therapy session in collaboration with the University Hospital Basels
Liechti Lab.
- Acquired the exclusive license to 8 clinical trials and human safety studies of LSD at
University Hospital Basel evaluating LSD.
- Filed a patent application and are developing technologies and analytics that seek to
personalize LSD assisted therapy experiences for a specific patient in collaboration with University
Hospital Basel Liechti Lab.

Microdosing Division 
- Entered into a clinical trial agreement with Maastricht University to undertake a Phase 2a
clinical trial for microdosing LSD in adult patients with ADHD intending to begin by the end of
2020.
- Appointed Principal Investigators for Phase 2a clinical trial for microdosing LSD Dr Kim
Krupyers (Maastricht University) and Dr Matthias Liechti (University Hospital Basel).
- Added additional clinical trial site at University Hospital Basel for Phase 2a clinical trial
at University Hospital Basel.

18-MC (Opioid Use Disorder Program)
- Initiated and began dosing of a Phase 1 human safety trial of our 18-MC program for Opioid Use
Disorder in Australia in the midst of COVID-19.

MDMA (3,4-Methylenedioxymethamphetamine)
- Acquired the exclusive license to 9 completed clinical trials of MDMA at University Hospital
Basel. Performing ongoing evaluation of data and opportunities to create new drug development
programs to include MDMA
- Filed a patent application and are developing technologies and analytics that seek to
personalize MDMA assisted therapy experiences for a specific patient in collaboration with
University Hospital Basel Liechti Lab.

DMT (N,N-Dimethyltryptamine, active ingredient in Ayahuasca)
- Providing startup funding to Liechti Lab for a Phase 1 clinical trial of DMT testing various
intravenous dosing regimens, expected to begin in Q4 of 2020 setting stage for future potential
Phase 2a proof of concept trials  

Corporate Development
- Appointed Johns Hopkins Professor and leading psychedelics researcher, Matt Johnson to its
scientific advisory board

MindMed Co-Founders and Co-CEOs will provide an update on operations and corporate activities,
and will answer questions for shareholders on Thursday, July 2 at 1pm EST. Please sign up for
Webinar here:

https://us02web.zoom.us/webinar/register/WN_pOzqk58eQaqgq_UZExDiHg 

When: Jul 2, 2020 01:00 PM Eastern Time (US and Canada) 
After registering, you will receive a confirmation email containing information about joining the
webinar.

About MindMed
Mind Medicine (MindMed) Inc. is a neuro-pharmaceutical company that discovers, develops and
deploys psychedelic-inspired medicines to improve health, promote wellness and alleviate suffering.
The company's has initiated or is initiating studies to evaluate potential treatments to help
patients with ADHD, anxiety, cluster headaches and substance abuse. The MindMed executive team
brings extensive biopharmaceutical industry experience to this groundbreaking approach to the
development of next-generation psychedelic medicines. MindMed trades on the NEO Exchange under the
symbol MMED. MindMed can also be traded in the US under the symbol OTC: MMEDF and in Germany under
the symbol DE:BGHM. For more information: www.mindmed.co.

Proactive Engagement 
MindMed is has engaged Proactive Investors North America Inc. ("Proactive") to provide ongoing
editorial coverage and to record and publish video interviews with MindMed's management team. 

Psychedelic Finance Engagement
The company has engaged CIFC Capital Corp operating under the trade name Psychedelic Finance to
generate digital content and social media posts about the company.

MindMed Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties
relating to future events and the future performance of Mind Medicine (MindMed) Inc. ("MindMed" or
the "Company"), and actual events or results may differ materially from these forward-looking
statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate,"
variations of such words, and similar expressions are intended to identify such forward-looking
statements, although not all forward-looking statements contain these identifying word. These
statements concern, and these risks and uncertainties include, among others, MindMed's and its
collaborators' ability to continue to conduct research and clinical programs (including those
discussed in this press release), MindMed's ability to manage its supply chain, net product sales of
products marketed by MindMed and/or its collaborators (collectively, "MindMed's Products"), and the
global economy; the nature, timing, and possible success and therapeutic applications of MindMed's
Products and product candidates and research and clinical programs now underway or planned; the
likelihood, timing, and scope of possible regulatory approval and commercial launch of MindMed's
product candidates and new indications for MindMed's Products; unforeseen safety issues resulting
from the administration of MindMed's Products and product candidates in patients, including serious
complications or side effects in connection with the use of MindMed's Products and product
candidates in clinical trials; determinations by regulatory and administrative governmental
authorities which may delay or restrict MindMed's ability to continue to develop or commercialize
MindMed's Products and product candidates; ongoing regulatory obligations and oversight impacting
MindMed's Products, research and clinical programs, and business, including those relating to
patient privacy; uncertainty of market acceptance and commercial success of MindMed's Products and
product candidates and the impact of studies (whether conducted by MindMed or others and whether
mandated or voluntary) on the commercial success of MindMed's Products and product candidates; the
availability and extent of reimbursement of MindMed's Products from third-party payers, including
private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit
management companies, and government programs such as Medicare and Medicaid; coverage and
reimbursement determinations by such payers and new policies and procedures adopted by such payers;
competing drugs and product candidates that may be superior to MindMed's Products and product
candidates; the extent to which the results from the research and development programs conducted by
MindMed or its collaborators may be replicated in other studies and lead to therapeutic
applications; the ability of MindMed to manufacture and manage supply chains for multiple products
and product candidates; the ability of MindMed's collaborators, suppliers, or other third parties
(as applicable) to perform manufacturing, filling, finishing, packaging, labelling, distribution,
and other steps related to MindMed's Products and product candidates; unanticipated expenses; the
costs of developing, producing, and selling products; the ability of MindMed to meet any of its
financial projections or guidance and changes to the assumptions underlying those projections or
guidance; the potential for any license or collaboration agreement to be cancelled or terminated
without any further product success; and risks associated with intellectual property of other
parties and pending or future litigation relating thereto, other litigation and other proceedings
and government investigations relating to the Company and/or its operations, the ultimate outcome of
any such proceedings and investigations, and the impact any of the foregoing may have on MindMed's
business, prospects, operating results, and financial condition. Any forward-looking statements are
made based on management's current beliefs and judgment, and the reader is cautioned not to rely on
any forward-looking statements made by MindMed. MindMed does not undertake any obligation to update
publicly any forward-looking statement, including without limitation any financial projection or
guidance, whether as a result of new information, future events, or otherwise.


Die englische Originalmeldung finden Sie unter folgendem Link: 
https://www.irw-press.at/press_html.aspx?messageID=52448
Die übersetzte Meldung finden Sie unter folgendem Link: 
https://www.irw-press.at/press_html.aspx?messageID=52448&tr=1
NEWSLETTER REGISTRIERUNG: 


Aktuelle Pressemeldungen dieses Unternehmens direkt in Ihr Postfach: 
http://www.irw-press.com/alert_subscription.php?lang=de&isin=CA60255C1095

Mitteilung übermittelt durch IRW-Press.com. Für den Inhalt ist der Aussender
verantwortlich.

Kostenloser Abdruck mit Quellenangabe erlaubt.